Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Malaria-specific antibody responses are short lived in children, leaving them susceptible to
repeated bouts of febrile malaria. The cellular and molecular mechanisms underlying this …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

Immune signatures measured at baseline and immediately prior to vaccination may predict
the immune response to vaccination. Such pre-vaccine assessment might allow not only …

Background The phase 3 trial of the RTS, S/AS01 malaria vaccine candidate showed
modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered …

The artemisinin (ART)-based antimalarials have contributed significantly to reducing global
malaria deaths over the past decade, but we still do not know how they kill parasites. To gain …

Background Vaccine adjuvants are compounds that significantly enhance/prolong the
immune response to a co-administered antigen. The limitations of the use of aluminium salts …

Background Controlled infection studies in malaria-naive adults suggest increased vaccine
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …